In discussion with Dr. Erika Hamilton, covering the ESMO 2023 Breast Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. Hamilton:
– Keynote 756 – phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early stage, ER+/HER2- breast cancer, with better pCR seen in pembrolizumab arm
– TROPION-Breast01 – Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer, with better PFS and ORR favoring Dato-DXd
– Keynote 522 – Event Free Survival update with neoadjuvant and adjuvant pembrolizumab in TNBC, continue to show benefit
